Beam Therapeutics’ base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant’s batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly’s oral GLP-1 pill receives FDA approval becoming the first non-peptide oral obesity treatment cleared in the United States the most significant clinical trial results 3 April 2026 has to offer from across the pipeline.
This week was marked by a high-profile gene therapy publication, a notable Phase 3 disappointment in autoimmune disease, and encouraging proof of concept data in neuropsychiatry. The FDA’s approval of Eli Lilly’s orforglipron as an oral GLP-1 pill for obesity marks one of the most significant regulatory decisions of the year so far, intensifying competition in a rapidly expanding market. Here, Life Science Daily News brings you the most significant clinical trial results 3 April 2026.
Beam Therapeutics’ Base Edited Cell Therapy for Sickle Cell Disease Published in The New England Journal of Medicine
Beam Therapeutics announced on 1 April the publication of data from its ongoing Phase 1/2 BEACON clinical trial of ristoglogene autogetemcel (risto-cel) in The New England Journal of Medicine. The study evaluated this investigational one-time base edited cell therapy in 31 patients with sickle cell disease (SCD) who experienced severe vaso-occlusive crises (VOCs).
The published data showed that treatment with risto-cel was followed by rapid engraftment, with neutrophil engraftment occurring at a median of 17.5 days and platelet engraftment at a median of 19 days. At six months, the mean fraction of on-target edited alleles in peripheral blood was 67.4 per cent. Patients achieved mean fetal haemoglobin (HbF) levels above 60 per cent, while pathological sickle haemoglobin (HbS) fell below 40 per cent. These levels were maintained throughout follow up, which extended to a mean of 6.6 months (range 0.3 to 20.4 months).
Crucially, no investigator-reported severe vaso-occlusive crises occurred later than 60 days after the last red cell transfusion. Total haemoglobin levels increased rapidly, with all patients experiencing resolution of anaemia, and key markers of haemolysis normalised or improved. The safety profile was consistent with busulfan conditioning and autologous haematopoietic stem cell transplantation. One patient died from idiopathic pneumonia syndrome, which was considered likely related to the busulfan conditioning regimen rather than the base edited product.
Risto-cel uses Beam’s base editing technology to modify the promoter regions of the HBG1/2 genes in a patient’s own blood stem cells, inducing production of protective fetal haemoglobin without creating double strand DNA breaks. The therapy has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Beam plans to submit a Biologics License Application (BLA) as early as the end of 2026.
Immunovant’s Batoclimab Fails to Meet Primary Endpoint in Two Phase 3 Thyroid Eye Disease Trials
Immunovant announced on 2 April that both of its Phase 3 GO clinical studies evaluating batoclimab in adults with active, moderate to severe thyroid eye disease (TED) failed to meet their prespecified primary endpoint of a 2 mm or greater proptosis responder rate at week 24. The safety profile was consistent with previous findings and no new safety signals were identified.
Despite missing the primary endpoint, the company noted that patients demonstrated greater levels of proptosis improvement from baseline after the initial 12 week high dose period than after the subsequent 12 week low dose period. This observation supports the benefit of deeper immunoglobulin G (IgG) suppression and suggests that the dose reduction strategy used in the latter half of the study may have limited efficacy. Hyperthyroid patients in the studies showed similar rates of thyroid hormone normalisation to those observed in the earlier Phase 2 Graves’ disease study.
Immunovant’s parent company Roivant also announced on the same day the expansion of the brepocitinib development programme into lichen planopilaris (LPP), a severe inflammatory scalp disorder causing irreversible hair loss and permanent scarring that affects approximately 100,000 adults in the United States. A seamless Phase 2b/3 potentially registrational trial enrolled its first subjects in March 2026. Immunovant stated it will review future plans for batoclimab with its partner HanAll Biopharma and remains focused on the rapid advancement of its next generation anti FcRn antibody, IMVT 1402.
Seaport Therapeutics’ GlyphAgo Achieves Proof of Concept in Phase 1 Trial for Generalised Anxiety Disorder
Seaport Therapeutics announced on 2 April positive topline data from the single ascending dose and crossover portions of its ongoing Phase 1 proof of concept trial evaluating GlyphAgo (SPT-320), a novel oral prodrug of agomelatine being developed for generalised anxiety disorder (GAD). The trial was conducted in healthy volunteers.
The trial demonstrated that GlyphAgo achieved a statistically significant 6.8 fold increase in bioavailability compared with unmodified agomelatine, exceeding the programme’s 2 fold target designed to mitigate liver exposure. GlyphAgo also substantially reduced pharmacokinetic variability by 10 fold compared with unmodified agomelatine, an important finding given that high variability has historically complicated dosing with the standard formulation. The drug was well tolerated across all evaluated doses, with no serious or severe adverse events and no liver related adverse effects reported.
Agomelatine, a clinically validated melatonin receptor agonist and serotonin 2C antagonist, is approved for GAD in Australia and major depressive disorder in Australia and the European Union, but its use has been constrained by dose dependent liver enzyme elevations and the need for frequent liver function monitoring. GlyphAgo uses Seaport’s proprietary Glyph platform, which routes drug absorption through the intestinal lymphatic system rather than the liver’s first pass metabolism. Based on these results, Seaport plans to advance GlyphAgo into two parallel Phase 2 studies: a proof of pharmacology trial examining sleep benefits in GAD patients, and a registration-enabling Phase 2b trial. If successful, GlyphAgo could become the first new therapy approved for GAD in the United States in decades.
FDA Approves Eli Lilly’s Orforglipron as First Non-Peptide Oral GLP-1 Pill for Obesity
The FDA approved Eli Lilly’s orforglipron on 1 April 2026, to be marketed under the brand name Foundayo. The approval was granted under the FDA’s Commissioner’s National Priority Voucher (CNPV) programme, making it the first new molecular entity approved under this initiative and reportedly the fastest approval of a new molecular entity since 2002.
Foundayo is a once daily, non-peptide oral GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition, used alongside a reduced-calorie diet and increased physical activity. Unlike Novo Nordisk’s oral semaglutide (Wegovy pill), which was approved in December 2025 and must be taken on an empty stomach with limited water, Foundayo can be taken at any time of day without food or water restrictions — a practical distinction that may support adherence.
The approval is supported by the ATTAIN Phase 3 clinical programme. The ATTAIN 1 trial evaluated orforglipron in adults with obesity or overweight without diabetes, and the ATTAIN 2 trial assessed the drug in patients with obesity or overweight and type 2 diabetes. Both studies demonstrated statistically significant reductions in body weight compared with placebo. The ATTAIN MAINTAIN trial further showed that orforglipron was superior to placebo in maintaining weight loss in patients who had reached a plateau on injectable semaglutide or tirzepatide. The drug’s safety profile was consistent with the GLP-1 class, with nausea, vomiting, diarrhoea, constipation, and dyspepsia among the most commonly reported adverse events.
The oral GLP-1 market is now home to two approved pills, with analysts projecting the combined oral obesity market could be worth tens of billions of dollars annually. Lilly has stated that Foundayo will be available through LillyDirect with broader retail availability to follow.
Looking Ahead
This week’s clinical trial results 3 April 2026 demonstrate the remarkable breadth of the current pharmaceutical pipeline. The NEJM publication of Beam’s base editing data in sickle cell disease represents a milestone for precision genetic medicine, while the batoclimab TED failure highlights the persistent challenges of late stage autoimmune development. Seaport’s GlyphAgo results could herald a new generation of anxiety treatments that overcome longstanding pharmacological limitations. And with orforglipron now approved and entering the market as Foundayo, the metabolic disease landscape has taken another significant step forward. Life Science Daily News will continue to bring you comprehensive, timely coverage of the clinical trial results 3 April 2026 that matter most to patients, clinicians, and the broader life science community.
